Cargando…
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities
Prompt recognition of acute chimeric antigen receptor T (CAR T)-cell–mediated toxicities is crucial because adequate and timely management can prevent or reverse potential life-threatening complications. In the outpatient setting, patients and informal caregivers have to recognize and report signs a...
Autores principales: | Spanjaart, Anne M., Pennings, Elise R.A., Kos, Milan, Mutsaers, Pim G.N.J., Lugtenburg, Pieternella J., van Meerten, Tom, van Doesum, Jaap A., Minnema, Monique C., Jak, Margot, van Dorp, Suzanne, Vermaat, Joost S.P., van der Poel, Marjolein W.M., van Oijen, Martijn G.H., Kuipers, Maria T., Nijhof, Inger S., Kersten, Marie José |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022884/ https://www.ncbi.nlm.nih.gov/pubmed/36508702 http://dx.doi.org/10.1200/OP.22.00501 |
Ejemplares similares
-
P1462: POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE
por: Spanjaart, A. M., et al.
Publicado: (2022) -
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
por: Spanjaart, Anne M., et al.
Publicado: (2023) -
P1128: EVALUATION OF STANDARD OF CARE IN SECOND-LINE FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE PRE-CAR-T ERA: A DUTCH POPULATION-BASED STUDY
por: Pennings, Elise R.A., et al.
Publicado: (2023) -
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities
por: de Boer, Janneke W., et al.
Publicado: (2023) -
Inflammatory reactions mimic residual or recurrent lymphoma on [(18)F]FDG-PET/CT after CD19-directed CAR T-cell therapy
por: de Boer, Janneke W., et al.
Publicado: (2023)